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Antiviral activity of a novel mixture 
of natural antimicrobials, in vitro, 
and in a chicken infection model 
in vivo
igori Balta1,2, Lavinia Stef3, ioan pet3, patrick Ward4, todd callaway5, Steven c. Ricke6, 
ozan Gundogdu7* & nicolae corcionivoschi1,2,3*
the aim of this study was to test in vitro the ability of a mixture of citrus extract, maltodextrin, sodium 
chloride, lactic acid and citric acid (AuraShield L) to inhibit the virulence of infectious bronchitis, 
Newcastle disease, avian influenza, porcine reproductive and respiratory syndrome (PRRS) and bovine 
coronavirus viruses. Secondly, in vivo, we have investigated its efficacy against infectious bronchitis 
using a broiler infection model. In vitro, these antimicrobials had expressed antiviral activity against 
all five viruses through all phases of the infection process of the host cells. In vivo, the antimicrobial 
mixture reduced the virus load in the tracheal and lung tissue and significantly reduced the clinical 
signs of infection and the mortality rate in the experimental group E2 receiving AuraShield L. All 
these effects were accompanied by a significant reduction in the levels of pro-inflammatory cytokines 
and an increase in igA levels and short chain fatty acids (ScfAs) in both trachea and lungs. our study 
demonstrated that mixtures of natural antimicrobials, such AuraShield L, can prevent in vitro viral 
infection of cell cultures. Secondly, in vivo, the efficiency of vaccination was improved by preventing 
secondary viral infections through a mechanism involving significant increases in SCFA production 
and increased IgA levels. As a consequence the clinical signs of secondary infections were significantly 
reduced resulting in recovered production performance and lower mortality rates in the experimental 
group E2.
Viral infections are increasingly frequent in humans and farm animals and because of their ability to suffer 
genetic modifications in a relatively short period of time there is a constant need to develop novel pharmaceuti-
cals in order to increase the efficacy of  treatment1. Some of the most common viral diseases in farmed animals 
are infectious bronchitis, Newcastle disease, avian influenza, porcine reproductive and respiratory syndrome 
(PRRS) and bovine coronavirus. Currently, vaccination for these diseases is only partially efficacious therefore 
additional preventions and treatments are needed.
Natural antimicrobials including plant extracts or organic acids are currently tested for their ability to inhibit 
viruses and prevent their pathogenic impact on the host. Plant phytochemicals, in particular flavonoids and 
polyphenols, contain an abundant pool of potent antiviral molecules (e.g., vitexin), a flavonoid isolated from 
pink coral tree Erythrina speciose leaves, demonstrated antiviral activity against Herpes Simplex Virus type 1 
(HSV-1) and Hepatitis A virus-H10 (HAV H10)2. Improving the efficiency of antimicrobial compounds rep-
resents a crucial step in developing alternative strategies, but this depends on a better understanding of their 
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mode of action. For example, gamma-coronavirus (IBV) that was pre-treated with elderberry (Sambucus nigra) 
fruit extracts resulted in damage to virus molecular structure causing an elimination of Vero cell  cytotoxicity3. 
The mechanism of elderberry extract efficacy was attributed to altered virion envelopes and membrane  vesicles4.
The identification of the active compounds with antiviral effects will lead to a better understanding on how 
natural antimicrobials inhibit viruses and diseases. Tangeretin is a polymethoxylated flavone found in citrus 
fruit peels that inhibits viral entry into cells by blocking viral  fusion5, and citrus extracts are active against 
avian influenza virus (AIV), Newcastle disease virus (NDV), infectious bursal disease virus (IBDV) in different 
 environments6. Moreover, vaccines containing citrus derived molecules were more efficient in stimulating the 
immune system with fewer side  effects7. Maltodextrins are plant polysaccharides that are commonly used as food 
additives that when used as a vaccine nanoparticle increased activity against influenza  virus8. Lactic acid also 
inhibited influenza A infection  replication8. Citric acid is another potent natural antimicrobial with anti-viral 
activity that inhibits the foot and mouth disease virus (FMDV)9.
An additional anti-viral mechanism by which natural antimicrobials can prevent viral infections refers to 
their ability to inhibit cellular oxidative events. For example, manganese superoxide dismutase (MnSOD) has 
been proven crucial in the fight against viral infections due to its role as superoxide scavenger and as anti-
inflammatory  agent10. The pro-inflammatory response, including the release of cytokines to avoid apoptosis 
is partially dependent on the levels of cellular hydrogen peroxide production as it leads to the stimulation of 
neutrophils and macrophages leading to the elimination of either microbes or  viruses11. Natural antimicrobials 
or plant extracts (phenolics, flavonoids, tannins) have the ability to negatively impact on oxidative stress helping 
the organism to protect itself from the detrimental effect of reactive oxygen  species12.
Combinations of natural antimicrobials, similar to AuraShield L (e.g. Auranta 3001), were previously 
described as efficient in preventing bacterial infections in chicken and mouse animal  models13–16. These results 
show that Auranta 3001 has a negative impact on the expression of virulence genes in Campylobacter spp.13, (hcp 
gene) and that improves the immune system response in challenged broilers. In infections caused by Listeria 
spp., these mixtures of antimicrobials were able to reduce the bacterial load in the liver and spleen of the infected 
mice and significantly reduced inflammation and reduced the mortality  rate15. It is thought that these mixtures 
of natural biochemical antimicrobials can directly affect viruses through their viral capsids or modify the recep-
tors on the host cells involved in adhesion being strongly suggested that a comprehensive understanding of their 
anti-viral mechanisms is strongly  recommended17.
Understanding the mechanisms involved in the anti-viral and anti-infectious activity of biochemical com-
pounds require extensive in vivo testing in order to prove their efficiency in reducing the clinical signs of disease 
without a negative impact on animal health. We hypothesized that given the fact that in combination natural 
antimicrobials can act antagonistically against each  other18 a detailed scientific report is often required, allowing 
the end user to design informed interventions at farm level. In the present study we examined the in vitro activity 
of a mixture of citrus extract, maltodextrin, sodium chloride, lactic acid and citric acid (AuraShield L) against 
viruses causing infectious bronchitis (B1648), Newcastle disease (ATCC, 699), avian influenza (H9N2, ATCC, 
VR-1642), porcine reproductive and respiratory syndrome (ATCC, VR-2386) and bovine coronavirus (ATCC, 
VR-874). We have investigated the effectiveness of this antimicrobial mixture by supplementing it via drinking 
water, against the infectious bronchitis virus in challenged broilers (B1648).
Results
The in vitro antiviral effect of AuraShield L. First we have investigated, in vitro, as described in Mate-
rials and Methods the antiviral effect of AuraShield L against the five of the most common infectious viruses 
in livestock including Infectious Bronchitis (B1648), Newcastle disease (ATCC, 699), Avian Influenza (H9N2, 
ATCC, VR-1642), porcine reproductive and respiratory syndrome (ATCC, VR-2386) and bovine coronavirus 
(ATCC, VR-874). The 50% effective concentration  (EC50) of AuraShield L was detected between 0.004 and 
0.007 μl/ml, with the highest concentrations (0.007 μl) required against VR-2386 (Table 1). Next we have dem-
onstrated the effect of the antimicrobial mixture on the viral replication by treating the cells and the viruses 
individually with AuraShield L prior to infection. Additionally, the antimicrobial mixture was tested by inclu-
sion during adsorption or after the adsorption period. Infected cells in the absence of AuraShield L were used 
as a control. The percent reduction in viral replication was calculated relative to the amount of virus produced 
in controls, and a non-cytotoxic concentration was used in all assays. Pre-treatment with AuraShield L caused 
a decrease in the number of plaques in all experimental investigations and for all viruses used (Fig. 1A). Pre-
treatment of cells with AuraShield L (0.01%) led to over 80% reduction in B1648, VR-699 and VR-2386 virus 
production compared to control. In the case of VR-1642 (Fig. 1A) the reduction was of approximately 70% and 
Table 1.  Cytotoxic and efficiency of AuraShield L. CC, cytotoxic concentration; EC, effective concentration; 
SI, selective index  (CC50/EC50).
Disease Virus CC50 (µl/ml) EC50 (µl/ml) SI
Avian infectious bronchitis B1648 0.27 0.004 67.5
Newcastle disease ATCC-699 0.33 0.004 82.5
Avian Influenza VR-1642 0.40 0.006 66.6
Porcine reproductive and respiratory syndrome VR-2386 0.54 0.007 77.1
Bovine coronavirus VR-874 0.19 0.004 47.5
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50% for VR-874. The impact was even more dramatic when viruses were pre-treated with AuraShield L with 
over 90% reduction for all viruses except VR-874 (65%). When AuraShield L was added during the adsorption 
period, virus titres were reduced by 52% for VR-874. Similar results were observed during viral replication, when 
the antimicrobial mixture was added only to the overlay medium. Collectively, these results suggest that the anti-
viral effect of AuraShield L is exerted through all phases of host cell infection.
AuraShield L reduces the viral load in the trachea and lungs of in vivo challenged broilers with 
the avian bronchitis virus (B1648). We have next examined the anti-viral effect of AuraShield L in broil-
ers in an in vivo infectious bronchitis model using the B1648 virus to cause infection. Viral RNA was measured 
in samples of tracheal and lung samples, using RT-qPCR (Fig. 1B). The viral RNA copies in the lung were at 
approximately 7.1  log10 copies/g tissue in group E1 with a significant decrease in the group E2 (p = 0.003) similar 
to the un-infected control group C. Inclusion of AuraShield L in the broiler’s drinking water reduced the viral 
load in the trachea from 8.7  log10 copies/g, in the untreated group E1, to 0.8  log10 copies/g in the tracheal tissue 
(p = 0.001) of the treated group E2. The virus levels were reduced below the levels recorded in the un-treated 
and un-challenged group C. The levels of significance were calculated considering group E1 as reference. These 
results indicate that the antimicrobial mixture reduced the virus load in the tracheal tissue having a negative 
impact the virus transition into the lung tissue.
Figure 1.  (A) the anti-viral effect of AuraShield L against B1648, ATCC, 699, VR-1642, VR-2386 and VR-874. 
AuraShield L was added at the non-cytotoxic concentration of 0.01%. Cells were pre-treated with AuraShield 
L prior to virus infection (pre-treatment cells), viruses were pre-treated prior to infection (pre-treated virus), 
AuraShield L was added during the adsorption period (adsorption) or after penetration of the viruses into cells 
(replication). Two-way ANOVA and Three-way ANOVA was used to analyse the significance of percentage 
decrease. (B) Viral RNA copies in the trachea and lungs. Viral RNA copies were measured by RT-qPCR. In (C) 
the average percentage of mortality in groups C, E1 and E2 is represented (birds per group at each time point). 
Asterisks indicate significant differences as indicated on the graph. Error bars represent the standard deviation of 
means from three replicate experiments.
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AuraShield L has a negative impact on the pro-inflammatory cytokines levels, stimulates 
immunity and reduces oxidative inflammation in challenged broilers. In order to gain more 
information on why we detect low levels of infection in the trachea and lungs of the experimental group we have 
designed experiments to investigate the effect against the main pro-inflammatory cytokines, on the immune 
system and cellular oxidation. The inclusion of AuraShield L in the drinking of the infected broilers (E2) reduced 
the levels of pro-inflammatory cytokines TGF-β3 (p = 0.0008), INFα (p = 0.01), INFβ (p < 0.0001) and INFγ 
(p = 0.0008) in the trachea (Fig. 2A). Similarly, to trachea, all pro-inflammatory factors in the lung were also 
decreased by the inclusion of AuraShield L compared to the control and group E1 (Fig. 2B). The significance was 
calculated against group E1 in order to account for the effect of AuraShield L. Overall inclusion of AuraShield 
L in the drinking water of group E2 broilers led to a reduction in the expression levels of all pro-inflammatory 
cytokines investigated indicating that this antimicrobial mixture could have impacted the lung and tracheal 
inflammation caused by infection. High serum IgA concentrations were detected at 5 days post AuraShield L 
inclusion in the drinking water (Fig. 2C). Secreted IgA levels were higher (405 vs 300 ng/ml, p = 0.02) in group 
E2 compared to group E1 and moreover, in group E1 (p = 0.0008) were significantly higher compared to group 
C. This is probably a result of vaccination and the response of infection, but equally AuraShield L treatment in 
group E2 boosted IgA levels above E1 (p = 0.02).
Figure 2.  Pro-inflammatory cytokine (TGF-β3, TNF-α, INFα, INFβ and INFγ) production in the trachea and 
lung tissue of B1648 infected/un-infected broilers which received or not AuraShield L in the drinking water for 
5 days post-infection, (A) in the trachea and (B) in the lungs. (C) Represents the IgA levels in broilers serum, 
(D) the SCFAs concentrations in the cecal contents. The levels of MnSOD (pg/ml) in the lung and trachea 
following exposure to AuraShield L are presented in (E). Asterisks indicate significant differences with the 
respective P values being indicated on the graph. Error bars represent the standard deviation of means from 
three different experiments. Student t test was used to calculate significance (**p < 0.005).
5Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16631  | https://doi.org/10.1038/s41598-020-73916-1
www.nature.com/scientificreports/
We have next investigated the association between SCFA production and manganese superoxide dismutase 
(MnSOD) expression as indicators of an improved immune response during viral infections. The levels of short 
chain fatty acids (SCFA) produced in broilers gut (cecum) were also investigated due to their association to a 
better immunity. The total measured SCFA levels in the cecal contents were significantly increased in group E2 
(p < 0.01) with the pH levels remained similar between the three groups (Table 2). Succinic acid, lactic acid and 
butyric acid concentrations were significantly increased by inclusion of AuraShield L (p < 0.05) (Fig. 2D). The 
concentrations of lactic acid, succinic acid, formic acid, lactic acid and butyric acid were significantly increased 
following inclusion of AuraShield L in the drinking water (p < 0.05). Inclusion of AuraShield L in the drink-
ing water of the infected broilers resulted in a significant increase in pulmonary and tracheal MnSOD activity 
(Fig. 2E). The levels of MnSOD, in the lung increased significantly from 380 pg/ml to 720 pg/ml (p = 0.0003) 
and to 676 pg/ml (p = 0.01) in the trachea following the inclusion of AuraShield L. These findings indicate that 
increased MnSOD expression in the pulmonary and tracheal tissue contributes to a better immune response 
and more efficient virus elimination.
AuraShield L reduces the clinical signs of disease in broilers challenged with the avian bron-
chitis virus (B1648) and reduces mortality. In order to quantify the beneficial effects described above 
we have closely monitored the clinical signs in the challenged broilers during AuraShield administration. Symp-
toms were mild in both groups except for tracheal rales which impacted 33% of the E1 broilers and 24% in E2 
(Table 3). Pulmonary rales were the second obvious clinical sign measurable in the first day of investigation with 
11% of broilers affected in group E1 and 18% in group E2. Beginning on day 2 clear signs of improvement were 
observed in AuraShield treated group (E2). The efficacy of AuraShield L treatment was compared between group 
E1 and E2 on day 5 and excluded the negative control C group. Broilers displaying no signs of ruffled feathers 
increased by 150% in group E2 when AuraShield L was included in the drinking water. Sneeze and coughs 
behaved similarly and demonstrated that the number of broilers showing no clinical signs increased 129.4% 
and 136.8%, respectively in group E2. Similarly, AuraShield L treatment decreased the number of broilers with 
tracheal and pulmonary rales. Dyspnoea was lower in the AuraShield L treated group (7% vs. 17%, respectively). 
No clinical nephritis were recorded during the course of experiment in any group, and clinical symptoms were 
detected in a small percentage of control broilers, but these were levels higher than that of group E2. The absence 
Table 2.  Effect of AuraShield L on total SCFA production and pH levels in the cecum (mg/cecum). SCFA 
short chain fatty acids.
Analysis
Groups
p valueC E1 E2
AuraShield L − − +
Vaccination + + +
IBV challenge − + +
Total SCFA 0.27 ± 0.19 0.43 ± 0.33 1.45 ± 0.27 < 0.01
pH 7.3 ± 0.01 7.01 ± 0.03 7.4 ± 0.04 ns
Table 3.  Clinical signs in infected and uninfected broilers treated with AuraShield L.
Group Day
Ruffled feathers Sneeze Cough Tracheal rale Pulmonary rale Dyspnoea
% of broilers with symptoms
C
1 0 4 3 4 2 3
2 0 3 2 4 3 4
3 4 7 8 6 12 4
4 9 6 8 7 15 7
5 14 7 10 12 22 5
E1
1 0 6 7 33 11 6
2 2 8 8 45 23 22
3 6 12 14 44 12 27
4 12 11 14 22 25 15
5 28 14 16 31 28 17
E2
1 0 0 0 24 18 0
2 1 1 1 9 12 1
3 6 2 4 2 4 4
4 4 2 3 2 5 4
5 4 3 3 2 4 7
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or presence of these clinical signs can also be reflected in the mortality rate recorded during the experiment. The 
inclusion of AuraShield L in the drinking water of broilers in group E2 maintained the broiler survival rate to 
93.7%. In contrast, broilers in group E1 had a survival rate of 66.6% and the control group 87.5% (Fig. 1c). The 
addition of AuraShield L in the drinking water also resulted in performance recovery in the infected broilers 
(supplementary Table 2).
Discussion
Ensuring animal health and welfare also includes having efficient technologies to reduce the incidence of infec-
tious diseases in order of safeguarding of national and international food  supplies19. A wide range of natural 
antimicrobial substances have been investigated and have shown activity against various  viruses20. Organic acids, 
including citric acid, are known not only for their role in increasing feed utilisation efficiency but also for their 
role in improving the immune response in infected  animals21. In this study, we have tested a mixture of natural 
antimicrobials containing citrus extract, maltodextrin, sodium chloride, lactic acid, and citric acid (AuraShield 
L) to test its activity in vitro against viruses responsible for avian infectious bronchitis, Newcastle disease, avian 
Influenza, porcine reproductive and respiratory syndrome (PRRS), and bovine coronavirus. In vivo the antimi-
crobial mixture was also tested for its ability to reduce the disease signs of infectious bronchitis using a broiler 
infection model.
Viruses need to penetrate into the cellular cytosol by breaking the endosomal membrane requiring undam-
aged surface structures to cause  infection22. AuraShield L acts upon the host and on the pathogen directly 
indicating a possible disruption of the early stages of viral infection. Experiments developed to evaluate the 
toxicity of AuraShield L indicated a moderate toxic behaviour towards viruses in cell cultures with the effective 
cytotoxicity being reached between 0.004–0.007 (µl/ml). Our study shows that the mode of anti-viral action was 
greatest when cells were treated with AuraShield L before infection or when viruses were incubated with non-
cytotoxic concentration of AuraShield L prior to infection. We have also observed that AuraShield L maintained 
its antiviral properties during adsorption or after penetration into the host cells.
Chickens are an important natural host of the infectious bronchitis virus which targets the upper respiratory 
tract, and intensive virus replication leads to signs characteristic of the clinical manifestation of this respiratory 
 disease23. When AuraShield L was included in the drinking water of artificially IBV (B1648) challenged chicken 
broilers, the viral mRNA was detected in the trachea and lungs of IBV infected broilers but was significantly 
decreased by AuraShield L treatment. The reduced presence of IBV virus in trachea of infected birds confirmed 
the ability of AuraShield L to reduce respiratory disease  progression24.
AuraShield L treatment reduced the expression of pro-inflammatory cytokines during infection. The trans-
forming growth factors (TGF-β) are polypeptides with role in cell growth and differentiation, and all five exam-
ined had similar biological activities including important pro-inflammatory and immunoregulatory  activities25. 
In our study the impact on TGF-β3 expression in AuraShield L treated broilers was also significant in both 
tracheal and lung tissue, with a similar pattern observed for most of the measured cytokines. The detrimental 
effect on pro-inflammatory cytokines can also be explained by the presence of maltodextrin in AuraShield L, as 
it has been shown that maltodextrin increased IgA production, an antibody that plays a crucial role in mucous 
membranes immune  function26. In our experiments, IgA levels were significantly increased in the serum of 
broilers treated with AuraShield L and offer protection to the  host27. The anti-infectious role of IgA was observed 
in the case of broiler coccidiosis where it has an essential role in the immune response to E. tenella28. Overall, 
the levels of pro-inflammatory cytokines were reduced by AuraShiled L to the level of the un-infected control 
emphasizing its anti-inflammatory effect.
Intestinal immunity if often involved in shaping lung immunity and preventing lung  inflammation29 through 
production of short chain fatty acids (SCFA). SCFA’s are known for their role in reducing allergic airway 
 inflammation30,31. This anti-inflammatory effect of SCFAs against viral infections was specifically described for 
the equine herpesvirus 1 (EHV1) where the effect was observed at physiological  levels32. In our study the inclu-
sion of AuraShield L in the drinking water significantly increased the SCFA (lactate, succinate, formate, acetate, 
propionate, and butyrate) production which justifies the observed effect on the immune system with positive 
effects on the viral pathogenicity. Another reason for the observed stimulated immune response in our study 
was the increased level of manganese superoxide dismutase (MnSOD) in the lung and tracheal tissue. It has 
been shown previously that in infectious bronchitis (IB) the oxidative status is improved by increasing the levels 
of manganese superoxide dismutase (MnSOD) with a significant impact on virus elimination via an increased 
immune  response33. A similar effect was observed in infections caused by influenza A virus where inclusion of 
MnSOD in aerosols led to a mild improvement of the disease. Other natural antimicrobials are also known for 
their antioxidant  effect12 also when included in the feed of farmed  poultr34 with a direct effect in controlling the 
levels of  MnSOD35.
At present, the primary method of protecting chickens from infectious bronchitis is through  vaccination36. 
However, vaccination does not eliminate all clinical signs, which can have detrimental impact on production 
efficiency, economic return, and animal  welfare37. Vaccination of broilers coupled with inclusion in the drinking 
water of AuraShield L reduced clinical signs associated with infectious bronchitis and reduced mortality rates.
In countries with intensive poultry production the incidence of infectious bronchitis virus (IBV) is very 
high with vaccination only partially diminishing the occurrence of infection and appearance of clinical  signs38. 
Identification and testing of novel and natural antimicrobial mixtures designed to reduce the severity of clinical 
manifestations and possibly to prevent viral infections are crucial for the industry to enhance animal health and 
welfare, while maintaining performance. Our study clearly shows that antimicrobial compounds and mixtures, 
such as AuraShield L, can reduce viral pathogenicity in vitro and can boost the efficacy of vaccination in vivo 
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by boosting the immune system through a mechanism that involves SCFA production and increased MnSOD 
expression.
Material and methods
Viruses and antimicrobial mixture. Infectious Bronchitis (B1648)39, Newcastle disease (ATCC, 699), 
Avian Influenza (H9N2, ATCC, VR-1642)40, porcine reproductive and respiratory syndrome (ATCC, VR-2386) 
and bovine coronavirus (ATCC, VR-874) were used. Viruses were propagated in pathogen free 10  days old 
embryonated chicken eggs. The viruses from the second passage were used in the present experiments. After 
48 h post-infection the allantoic fluids were harvested by low-speed centrifugation and stored at − 70 °C. In this 
study we have used a commercial product (AuraShield L), a mixture of maltodextrin (4%) and sodium chloride 
(0.5%). As additives lactic acid (30%) and citric acid (15%) and citrus extract (8%) were also included and the 
balance to 100% is made up with  dH2O. This commercially available mixture is identified in the manuscript 
AuraShield L supplied by Auranta LTD.
cytotoxicity assay  (cc50,  ec50 and Si). AuraShield L was used for the determination of  EC50 and SI 
(selective index). The mixture was titrated from 1 to 1:128  CC50 and used for virus exposure. After the addition 
of 10 μl MTT reagent (Sigma Aldrich) the samples were incubated for 4 h at 37 °C. The  EC50 concentrations 
were calculated against extract concentrations.In order to determine the cytotoxic activity of AuraShield L the 
antimicrobial product was dissolved in water and added to the cell culture medium at a final concentration of 
2% in order to quantify the effect on monolayer culture. The Hep-2 cells (ATCC CCL-23) were grown in Dub-
leco Minimum Essential Medium (DMEM—Sigma-Aldrich) supplemented with foetal bovine serum to a final 
concentration of 10%. Cells were incubated 37 °C with the medium being renewed every 48 h. The Hep-2 cells 
were grown in 0.001–0.2% AuraShield L containing medium. The antimicrobial mixture was tested in triplicate 
and on three different occasions. The absorbance of each well was measured at 620 nm in a microplate reader 
(Fluostar Omega, BMG Labtech) and the percentage of cell survival was calculated.
Direct plaque assay. The plaque reduction assay was performed as previously  described41. Brielfy, 2 × 103 
plaque forming units were incubated with different concentrations of AuraShield L for 2 h at room temperature. 
Serial dilutions of the treated viruses were adsorbed to the cells for 2 h at 37 °C. All assays was performed in 
triplicates. Incubation was performed for 4 days at 37 °C, followed by 10% formalin fixation. Plaque counting 
was performed after staining with 1% crystal violet.
in vitro antiviral activity. Antiviral activity was performed as previously  described41 except that in our 
experiments Hep-2 cell line was used. Briefly, Hep-2 cells were pre-treated with AuraShield L before viral infec-
tion and separately the viruses were incubated with AuraShield L before infection. In order to test for viral 
absorption or penetration the cells and viruses were incubated together. AuraShield L was always used at the 
nontoxic concentration of 0.09% and was added to the cells followed by incubation for 2 h at 37 °C. The superna-
tant was removed, cells were washed and infected with each virus individually. In the case when the antimicro-
bial mixture was used to pre-treat the viruses the incubation took place for 1 h at room temperature followed by 
infection of cells. The absorption period was analysed by mixing individually the viruses with 0.09% AuraShield 
followed by infection of cells. In the case of replication after infection the inoculum was removed and replaced 
with media containing 0.5% methylcellulose. Each assay was performed in three replicates on 3 different occa-
sions. Plaque reduction assays were carried out as mentioned above and number of plaques of AuraShield L 
treated cells and viruses were compared to untreated controls. Data were subjected to statistical analyses using 
the Graph Prism software package.
In vivo infections with IBV B1648. Two-week-old ROSS 308 broilers were separated in three groups 
(n = 150 broilers/group): Control (C), first experimental group (E1) included broilers challenged with IBV B1648 
and the second experimental (E2) included broilers challenged with IBV B1648 and supplemented with AuraSh-
ield L as described in Fig. 3. All groups were vaccinated against IBV with Biovac H120 (V1) and Nobilis IB491 
(V2). Each broiler in groups E1 and E2 was inoculated intratracheally with (200 μl) with  103 EID50/400 μl B1648 
on day 14. AuraShield L was administered to the experimental group E2 through drinking water following the 
protocol described in Fig. 3. Birds were housed in separate negative pressure isolation rooms, and drinking water 
and feed were ad libitum duration the experiment. The aim of our study was to assess the effect of Aura Shield L 
on infection rate and symptoms, and this use of a low IBV challenge dose keeps a low mortality rate as previously 
 described39. Control broilers were inoculated with 200 µl PBS (Phosphate Buffer Saline) and served as a nega-
tive control group. At 28 days, 30 chickens from each group were humanely euthanized and tracheal and lung 
samples were stored at − 70 °C for viral RNA quantification by RT-qPCR. Pro-inflammatory cytokines (TGF-β3, 
TNF-α, INFα, INFβ, INFγ) in tissue of trachea, lung of IBV B1648-infected chickens was determined by using a 
commercially available enzyme-linked immunosorbent assay systems from Quantikine, R&D Systems. Results 
of cytokine concentration were expressed as pg (picograms) per milliliter of culture medium. Each study run 
was performed in triplicate. The experimental design was evaluated and approved by the Ethical and Animal 
Welfare Committee of the Banat University of Agricultural Sciences and Veterinary Medicine, King Michael I 
of Romania, Timisoara and we confirm that all methods were performed in accordance with the relevant guide-
lines and regulations.
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Scoring and clinical signs. Clinical signs, such as ruffled feathers, sneezing, coughing, tracheal and pul-
monary rales and dyspnoea were recorded daily during the 5 days of AuraShield L administration and once 
infection was established. Clinical signs and gross lesions were recorded. Clinical signs were quantified and 
expressed as a percentage of the total number of birds. The percentage difference (Eq. 1) was used to indicate the 
efficiency of AuraShield L in reducing the clinical signs of disease.
RT-qPCR assay for ORF 1a gene. As previously  described39 RT-qPCR primers were used to detect the 
B1648 strain in the tracheal samples using the following primers cDNA_FW ggtgttaggcttatagttcctcag, cDNA_RV 
taaacattagggttgacaccagt, T7_FW taatacgactcactatagggggtgttaggcttatagttcctcag, qPCR_FW gctattgtagaggtagtgtat-
gtgag and qPCR_RV agggttgacaccagtaaagaat. Viral RNA was extracted from tracheal secretions using the RNe-
asy Plus Mini Kit (Qiagen, United Kingdom). The RNA was reverse transcribed using Transcriptor First Strand 
cDNA Synthesis Kit (Roche) according to the manufacturer’s protocol. The mRNA levels were determined by 
quantitative RT-PCR using QuantiNovaSYBR Green PCR Kit (Qiagen, United Kingdom) on a LightCycler 96 
(Roche). The conditions for genes consisted of incubating at 95 °C for 8 min were followed by 40 cycles, each 
10 s at 95 °C and 60 s at 58 °C. A total of 5 μl of SYBR Green master mixture was used in each reaction along 
with 0.5 μl of 10 μM primer mixture, 3 μl of molecular grade water, and 1 μl of DNA sample. Viral RNA extracts 
from tracheal secretions were analysed in triplicate RT-qPCR reactions as described above. Quantification of the 
number of viral RNA copies in tissues (RNA copies/g) was similar like in other samples.
Determination of igA levels in the serum. The total levels of IgA were measured by IgA Enzyme-
Linked Immunosorbent Assay (ELISA) kit (ab157691 ABCAM) according to the manufacturer’s instructions.
ScfA determinations. The SCFA were analysed by gas chromatography as previously  described42. In brief, 
1 g of ceca was mixed 1 ml of  H2O and 1 ml of 20 mmol/l pivalic acid solution as an internal standard. The solu-
tion was mixed and 1 ml of  HClO4 (perchloric acid) was added in order to extract SCFA by shaking by vortexing 
for 5 min. The  HClO4 acid was precipitated by adding 50 ml of 4 mol KOH into 500 ml of supernatant. The addi-
tion of saturated oxalic acid, at 4 °C for 60 min, and centrifugation at 18,000 g for 10 min. Samples were analysed 







Figure 3.  Schematic outline of the in vivo experimental design. Broilers were vaccinated at day 5 (V1) and day 
15 (V2). Groups E1 and E2 were challenged with IBV B1648 day 14. Group E2 received AuraShield L in the 
drinking water for 5 days. At day 28 performance was recorded and 30 broilers euthanized for analysis.
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Superoxide manganese dismutase (SOD2/MnSOD) determination in the lung tissue. The 
superoxide manganese dismutase was quantified in the lung and trachea using the chicken SOD 2 Eliza Kit 
(Assay Solution) according to the manufacturer instructions. Briefly, the tissues were rinsed in ice-cold PBS 
(0.02 mol/l, pH 7.0–7.2) to remove excess blood, minced the tissues to small pieces and homogenized them in 
a certain amount of PBS and stored at -80 °C until further use. A standard curve was prepared for each experi-
ment. Volumes of 100 μl sample and standard were added per each well in a 96 well plate, except the control well 
where 0.1 ml of the sample diluent was added. Each well was washed with wash buffer two times for a total of 
three washes. After the last wash the wash buffer was removed by aspirating or by inverting the plate and blotting 
it against clean paper towels. In the next step 100 μl of the detection antibody was added to each well followed by 
incubation at room temperature for 2 h. Next, streptavidin-HRP (100 μl) was added to each well and incubated 
at room temperature for 30 min. Each measurement was done in triplicate.
Statistical analysis. Statistical analyses were performed using GraphPad software. Data were represented 
as mean ± SD. p-values < 0.05 were considered statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001). ANOVA 
and Student t were used. An ANOVA was performed to analyse the percentage decrease compared to control 
using both Two-way ANOVA (p < 0.0001) and Three-way ANOVA (p < 0.0001).
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